Ferrer Unit to Distribute Agendia's MammaPrint, CupPrint Dxs in Spain

Jul 17, 2007

NEW YORK (GenomeWeb News) — Ferrer in Code will distribute Agendia’s MammaPrint breast cancer recurrence assay and its CupPrint cancer of unknown primary test in Spain, Agendia said today.

Agendia CEO Bernhard Sixt said the partners are currently discussing “future steps in order to intensify the co-operation in other parts of the world.”

Ferrer in Code is a subsidiary of the pharmaceutical company Ferrer.

Financial terms of the agreement were not released.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Dual Listings Sought

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

Allocating the Grant Pie

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

More Proposed for NSF

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

This Week in PNAS

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.

Main menu